Alps Advisors Inc Cel Sci Corp Transaction History

Alps Advisors Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$8.68 - $27.49 $606,541 - $1.92 Million	-69,878 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$12.0 - $27.64 $792 - $1,824	66 Added 0.09%	69,878 $1.06 Million
Q4 2020 Feb 03, 2021	BUY	$11.05 - $16.62 $227,154 - $341,657	20,557 Added 41.74%	69,812 $814,000
Q3 2020 Nov 04, 2020	SELL	$11.69 - $14.54 $21,193 - $26,361	-1,813 Reduced 3.55%	49,255 $628,000
Q2 2020 Aug 05, 2020	BUY	$9.75 - $17.6 $497,913 - $898,796	51,068 New	51,068 $762,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.